BillionToOne Introduces Northstar Select® for Advanced Lung Cancer Study in Japan BillionToOne announces the inclusion of Northstar Select® as a liquid biopsy test in a major lung cancer study in Japan, enhancing patient treatment options.

BillionToOne Introduces Northstar Select® for Advanced Lung Cancer Study in Japan #Japan #Lung_Cancer #BillionToOne #Kashiwa #Northstar_Select

BillionToOne Unveils Northstar Select® with Exceptional Sensitivity in Oncology Testing BillionToOne's Northstar Select® has shown superior sensitivity in genomic profiling when tested against existing assays, providing better insights for cancer treatment.

BillionToOne Unveils Northstar Select® with Exceptional Sensitivity in Oncology Testing #United_States #Liquid_Biopsy #Menlo_Park #BillionToOne #Northstar_Select

BillionToOne Welcomes New Executives to Transform UNITY and Northstar Platforms BillionToOne, a molecular diagnostics firm, announces leadership additions to enhance UNITY and Northstar platforms, driving growth and innovation.

BillionToOne Welcomes New Executives to Transform UNITY and Northstar Platforms #United_States #Menlo_Park #BillionToOne #Northstar_Select #UNITY_Complete

BillionToOne's Northstar Select® Gains Medicare Coverage for Enhanced Cancer Treatment Access BillionToOne's Northstar Select® has received Medicare coverage, enhancing accessibility to cutting-edge genomic profiling for cancer therapy selection.

BillionToOne's Northstar Select® Gains Medicare Coverage for Enhanced Cancer Treatment Access #USA #Menlo_Park #NHS #Medicare #Northstar_Select